Mayo Clinic’s Unity Biotechnology UBX Stock Holding History

Mayo Clinic’s Portfolio UBX Stock Details UBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$182K	Hold	124,081	–	–	6.29%	3
2024 Q2	$168K	Hold	124,081	–	–	5.53%	3
2024 Q1	$203K	Hold	124,081	–	–	3.31%	5
2023 Q4	$239K	Hold	124,081	–	–	1.48%	5
2023 Q3	$298K	Hold	124,081	–	–	0.57%	4
2023 Q2	$316K	Sell	124,081 -33,117	-21%	-$87.5K	0.32%	5
2023 Q1	$256K	Hold	157,198	–	–	0.21%	9
2022 Q4	$431K	Buy	+157,198	New	+$457K	0.23%	6
2021 Q2	$7.29M	Hold	157,198	–	–	8.07%	3
2021 Q1	$9.43M	Hold	157,198	–	–	10.86%	3
2020 Q4	$8.24M	Hold	157,198	–	–	9.91%	3
2020 Q3	$5.44M	Hold	157,198	–	–	7.33%	4
2020 Q2	$13.6M	Hold	157,198	–	–	13.06%	4
2020 Q1	$9.12M	Hold	157,198	–	–	23.05%	2
2019 Q4	$11.3M	Buy	+157,198	New	+$11.1M	12.85%	2

Other funds holding UBX

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Ballentine Partners Waltham, Massachusetts $8.18B AUM 27.59% 1-Year Est. Return

FFVM

Founders Fund V Management San Francisco, California $2.16M AUM 77.37% 1-Year Est. Return

Mayo Clinic's UBX Position: Q3 2024 in Review

Mayo Clinic held its Unity Biotechnology (UBX) position steady in Q3 2024 at 124,081 shares worth $182K. The position accounts for 6.29% of the portfolio, ranked #3.

Mayo Clinic first reported a position in UBX in Q4 2019 and has held it in 15 quarters since. The position peaked at $13.6M in Q2 2020. 38 funds tracked by Wall St. Rank hold UBX as of Q3 2024.

Mayo Clinic held 124,081 shares of Unity Biotechnology worth $182K as of Q3 2024.
Mayo Clinic left its Unity Biotechnology share count unchanged in Q3 2024.
Unity Biotechnology made up 6.29% of Mayo Clinic's portfolio in Q3 2024, its #3 holding.
Mayo Clinic first reported a position in Unity Biotechnology in Q4 2019 and has held it in 15 quarters since.
Mayo Clinic's Unity Biotechnology position peaked at $13.6M in Q2 2020.
38 funds tracked by Wall St. Rank held Unity Biotechnology as of Q3 2024.

Based on Mayo Clinic's 13F filing for Q3 2024, filed 12 Nov 2024.